HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Loizides Mangold, Ursula ^b   Clément, Sophie ^a   Alfonso Garcia, Alba ^c   Branche, Emilie ^a   Conzelmann, Stéphanie ^a   Parisot, Clotilde ^a   Potma, Eric O ^c   Riezman, Howard ^b   Negro, Francesco ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CHOLESTEROL ESTER; CORE PROTEIN; FAT DROPLET; GLYCOSYLCERAMIDE; SPHINGOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID COMPOSITION; LIPIDOMICS; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPHINGOLIPID METABOLISM; BIOSYNTHESIS; HEPACIVIRUS; METABOLISM; TUMOR CELL LINE;

HEPATITIS C VIRUS;

CELL LINE, TUMOR; CHOLESTEROL ESTERS; HEPACIVIRUS; HUMANS; LIPID DROPLETS; SPHINGOLIPIDS; VIRAL CORE PROTEINS;

EID: 84919342501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115309     Document Type: Article

References (61)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology. 57: p. 1333- 42.
2. Grebely J, Dore GJ (2011) What is killing people with hepatitis C virus infection? Semin Liver Dis. 31: p. 331-9.
3. Machado MV, Oliveira AG, Cortez-Pinto H (2011) Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients, J Gastroenterol Hepatol. 26: p. 1361-7.
4. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, et al. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3, J Hepatol. 33: p. 106-15.
5. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, et al. (2005) An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation, J Hepatol. 42: p. 744-51.
6. Goossens N, Negro F (2014) Is the genotype 3 of the hepatitis C virus the new villain? Hepatology.
7. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C, Hepatology. 38: p. 75-85.
8. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, et al. (2001) Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C, J Hepatol. 34: p. 428-34.
9. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, et al. (2009) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up, Hepatology. 50: p. 1030-7.
10. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, et al. (2006) Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis, Gastroenterology. 130: p. 1661-9.
11. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, et al. (2002) Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis, Faseb J. 16: p. 185-94.
12. Waris G, Felmlee DJ, Negro F, Siddiqui A (2007) Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress, J Virol. 81: p. 8122-30.
13. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, et al. (2008) Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2, J Gen Virol. 89: p. 1225-30.
14. McPherson S, Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, et al. (2008) Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis, J Hepatol. 49: p. 1046-54.
15. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, et al. (2005) Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver, Dig Dis Sci. 50: p. 1361-71.
16. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, et al. (2005) Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection, Gastroenterology. 128: p. 334-42.
17. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, et al. (2006) Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection, Aliment Pharmacol Ther. 23: p. 107-14.
18. Clement S, Peyrou M, Sanchez-Pareja A, Bourgoin L, Ramadori P, et al. (2011) Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets, Hepatology. 54: p. 38-49.
19. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, et al. (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice, J Gen Virol. 78 (Pt 7): p. 1527-31.
20. Qiang G, Yang L, Witek RP, Jhaveri R (2009) Recombinant adenoviruses expressing steatosisassociated hepatitis C virus genotype 3 core protein produce intracellular lipid accumulation in cultured and primary hepatocytes, Virus Res. 139: p. 127-30.
21. Clement S, Pascarella S, Conzelmann S, Gonelle-Gispert C, Guilloux K, et al. (2010) The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8, J Hepatol. 52: p. 635-43.
22. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K (2002) Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods, Gene Ther. 9: p. 1155-62.
23. Brasaemle DL, Wolins NE (2006) Isolation of lipid droplets from cells by density gradient centrifugation, Curr Protoc Cell Biol. Chapter 3: p. Unit 3 15.
24. Clement S, Juge-Aubry C, Sgroi A, Conzelmann S, Pazienza V, et al. (2008) Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes, Hepatology. 48: p. 799-807.
25. Loizides-Mangold U, David FP, Nesatyy VJ, Kinoshita T, Riezman H (2012) Glycosylphosphatidylinositol anchors regulate glycosphingolipid levels, J Lipid Res. 53: p. 1522-34.
26. Guan XL, Riezman I, Wenk MR, Riezman H (2010) Yeast lipid analysis and quantification by mass spectrometry, Methods Enzymol. 470: p. 369-91.
27. Murata T, Takahashi S (1973) Analysis of triglyceride mixtures by gas chromatography-mass spectrometry, Anal Chem. 45: p. 1816-23.
28. Read SA, Tay E, Shahidi M, George J, Douglas MW (2014) Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production, J Gen Virol. 95: p. 1900-10.
29. Bartz R, Li WH, Venables B, Zehmer JK, Roth MR, et al. (2007) Lipidomics reveals that adiposomes store ether lipids and mediate phospholipid traffic, J Lipid Res. 48: p. 837-47.
30. Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, et al. (2010) Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics, PLoS Pathog. 6: p. e1000719.
31. Moriya K, Todoroki T, Tsutsumi T, Fujie H, Shintani Y, et al. (2001) Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans, Biochem Biophys Res Commun. 281: p. 1207-12.
32. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, et al. (2008) PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice, J Clin Invest. 118: p. 683-94.
33. Harris C, Herker E, Farese RV Jr, Ott M (2011) Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis, J Biol Chem. 286: p. 42615-25.
34. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, et al. (2007) A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology. 46: p. 1081-90.
35. Birnbaum Y, Nanhwan MK, Ling S, Perez-Polo JR, Ye Y, et al. (2014) PTEN Upregulation May Explain the Development of Insulin Resistance and Type 2 Diabetes with High Dose Statins, Cardiovasc Drugs Ther. 28: p. 447-57.
36. Naples M, Federico LM, Xu E, Nelken J, Adeli K (2008) Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization, Atherosclerosis. 198: p. 94-103.
37. Goswami R, Singh D, Phillips G, Kilkus J, Dawson G (2005) Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines, J Neurosci Res. 81: p. 541- 50.
38. Peyrou M, Clement S, Maier C, Bourgoin L, Branche E, et al. (2013) PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism, J Hepatol. 59: p. 420-426.
39. Nakamuta M, Yada R, Fujino T, Yada M, Higuchi N, et al. (2009) Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy? Int J Mol Med. 24: p. 825-8.
40. Woodhouse SD, Narayan R, Latham S, Lee S, Antrobus R, et al. (2010) Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro, Hepatology. 52: p. 443-53.
41. Sugiyama K, Ebinuma H, Nakamoto N, Sakasegawa N, Murakami Y, et al. (2014) Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus, PLoS One. 9: p. e94460.
42. Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, et al. (2009) An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads, Intervirology. 52: p. 43-8.
43. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, et al. (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon, Hepatology. 44: p. 117-25.
44. O'Leary JG, Chan JL, McMahon CM, Chung RT (2007) Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial, Hepatology. 45: p. 895-8.
45. Forde KA, Law C, O'Flynn R, Kaplan DE (2009) Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol. 15: p. 5020-7.
46. Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, et al. (2007) A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication, Gastroenterology. 132: p. 311-20.
47. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial, J Clin Gastroenterol. 43: p. 990-4.
48. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, et al. (2009) Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome, Am J Physiol Endocrinol Metab. 297: p. E211-24.
49. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, et al. (2005) Host sphingolipid biosynthesis as a target for hepatitis C virus therapy, Nat Chem Biol. 1: p. 333-7.
50. Hirata Y, Ikeda K, Sudoh M, Tokunaga Y, Suzuki A, et al. (2012) Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis, PLoS Pathog. 8: p. e1002860.
51. Umehara T, Sudoh M, Yasui F, Matsuda C, Hayashi Y, et al. (2006) Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model, Biochem Biophys Res Commun. 346: p. 67-73.
52. Amemiya F, Maekawa S, Itakura Y, Kanayama A, Matsui A, et al. (2008) Targeting lipid metabolism in the treatment of hepatitis C virus infection, J Infect Dis. 197: p. 361-70.
53. Ruvolo PP (2003) Intracellular signal transduction pathways activated by ceramide and its metabolites, Pharmacol Res. 47: p. 383-92.
54. Dobrowsky RT, Hannun YA (1992) Ceramide stimulates a cytosolic protein phosphatase, J Biol Chem. 267: p. 5048-51.
55. Burg JS, Espenshade PJ (2011) Regulation of HMG-CoA reductase in mammals and yeast, Prog Lipid Res. 50: p. 403-10.
56. Leventis PA, Grinstein S (2010) The distribution and function of phosphatidylserine in cellular membranes, Annu Rev Biophys. 39: p. 407-27.
57. Rabionet M, Bayerle A, Marsching C, Jennemann R, Grone HJ, et al. (2013) 1-O-acylceramides are natural components of human and mouse epidermis, J Lipid Res. 54: p. 3312-21.
58. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR (2000) Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction, Faseb J. 14: p. 1603-10.
59. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, et al. (2011) Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome, J Biol Chem. 286: p. 3018- 32.
60. Binns D, Januszewski T, Chen Y, Hill J, Markin VS, et al. (2006) An intimate collaboration between peroxisomes and lipid bodies, J Cell Biol. 173: p. 719-31.
61. Schrader M (2001) Tubulo-reticular clusters of peroxisomes in living COS-7 cells: dynamic behavior and association with lipid droplets, J Histochem Cytochem. 49: p. 1421-29.